EGLN1 and melanoma: HIF inhibitor or HIF-1α knockdown suppresses AKT–mTOR pathway in BrafV600E; Phd2−/− melanoma cells, supporting the involvement of HIF pathway activation in mediating the effect of Phd2 deletion, at least in melanoma setting.